Peer-Reviewed Publications

CPCE investigators are international experts in their clinical effectiveness-related fields, and have authored hundreds of pediatric research articles in leading peer-reviewed journals. From here you can access CPCE journal article abstracts by author, title, or year.

Found 163 results
Author Title [ Year(Asc)]
Filters: Author is Aplenc, Richard  [Clear All Filters]
2021
Rosenfeld E, Getz KD, Miller TP, et al. "Incidence and risk factors for hypoglycemia during maintenance chemotherapy in pediatric acute lymphoblastic leukemia." Pediatr Blood Cancer. 2021:e29467.
Chow EJ, Aplenc R, Vrooman LM, et al. "Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group." Cancer. 2021.
Getz KD, Szymczak JE, Li Y, et al. "Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia." JAMA Netw Open. 2021;4(10):e2128385.
Getz KD, Lewey J, Tam V, et al. "Neighborhood education status drives racial disparities in clinical outcomes in PPCM." Am Heart J. 2021.
Getz KD, Lewey J, Tam V, et al. "Neighborhood education status drives racial disparities in clinical outcomes in PPCM." Am Heart J. 2021;238:27-32.
Elgarten CW, Wood AC, Li Y, et al. "Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group." Pediatr Blood Cancer. 2021:e29281.
Ibrahimova A, Winestone LE, Miller TP, et al. "Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia." Pediatr Blood Cancer. 2021:e28940.
Kadauke S, Myers RM, Li Y, et al. "Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial." J Clin Oncol. 2021:JCO2002477.
Pan Y, Kadash-Edmondson KE, Wang R, et al. "RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets." Trends Pharmacol Sci. 2021;42(4):268-282.
Rasche M, Zimmermann M, Steidel E, et al. "Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG." Cancers (Basel). 2021;13(10).
2020
Chisholm KM, Heerema-McKenney AE, Choi JK, et al. "Acute erythroid leukemia is enriched in NUP98 fusions: a report from the Children's Oncology Group." Blood Adv. 2020;4(23):6000-6008.
Aplenc R, Meshinchi S, Sung L, et al. "Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group." Haematologica. 2020.
Ding Y-Y, Ramakrishna S, Long AH, et al. "Delayed cancer diagnoses and high mortality in children during the COVID-19 pandemic." Pediatr Blood Cancer. 2020:e28427.
Diorio C, Shaw PA, Pequignot E, et al. "Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children." Blood Adv. 2020;4(20):5174-5183.
Getz KD, Sung L, Alonzo TA, et al. "Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group." J. Clin. Oncol.. 2020:JCO1902856.
Hoff FW, van Dijk AD, Qiu YHua, et al. "Heat Shock Factor 1 (HSF1-pSer326) Predicts Response to Bortezomib-Containing Chemotherapy in Pediatric AML: A COG Study." Blood. 2020.
Cahen VC, Li Y, Getz KD, et al. "Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment." Pediatr Blood Cancer. 2020:e28315.
Arnold SD, Brazauskas R, He N, et al. "The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis: Pediatric acute leukemia transplant risks and utilization." Biol. Blood Marrow Transplant.. 2020.
Brodersen LEidenschin, Gerbing RB, M Pardo L, et al. "Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 report." Blood Adv. 2020;4(20):5050-5061.
Cooper TM, Absalon MJ, Alonzo TA, et al. "Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group." J. Clin. Oncol.. 2020:JCO1903306.
Bona K, Li Y, Winestone LE, et al. "Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma." J Natl Cancer Inst. 2020.
Wang ES, Aplenc R, Chirnomas D, et al. "Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia." Leuk. Lymphoma. 2020:1-9.
Aplenc R. "Venetoclax for paediatric acute myeloid leukaemia: a step forward." Lancet Oncol.. 2020;21(4):476-478.

Pages